Long-Term Tolvaptan Treatment in Refractory Heart Failure-Reference-Cited by-同舟云学术

Long-Term Tolvaptan Treatment in Refractory Heart Failure

Published:2019-10-10 Issue:10 Volume:1 Page:431-437
ISSN:2434-0790
Container-title:Circulation Reports
language:en
Short-container-title:Circ Rep

Author:

Imamura Teruhiko¹,Kinugawa Shintaro²,Muramatsu Toshihiro³,Shiga Tsuyoshi⁴,Ogimoto Akiyoshi⁵,Anzai Toshihisa⁶,Hagiwara Nobuhisa⁴,Tsutsui Hiroyuki²,Komuro Issei⁷,Kinugawa Koichiro⁸

Affiliation:

1. Division of Cardiology, University of Chicago Medical Center

2. Department of Cardiovascular Medicine, Faculty of Medicine and Graduate School of Medicine, Hokkaido University

3. Department of Cardiology, Saitama Medical University International Medical Center

4. Department of Cardiology, Tokyo Women’s Medical University

5. Department of Cardiology, Pulmonology, Hypertension and Nephrology, Ehime University Graduate School of Medicine

6. Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center

7. Division of Cardiology, Graduate School of Medicine, the University of Tokyo

8. Second Department of Internal Medicine, University of Toyama

Publisher

Japanese Circulation Society

Subject

Marketing,Organizational Behavior and Human Resource Management,Strategy and Management,Drug Discovery,Pharmaceutical Science,Pharmacology

Link

https://www.jstage.jst.go.jp/article/circrep/1/10/1_CR-19-0064/_pdf

Reference22 articles.

1. 1. Gottlieb SS, Brater DC, Thomas I, Havranek E, Bourge R, Goldman S, et al. BG9719 (CVT-124), an A1 adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapy. Circulation 2002; 105: 1348–1353.

2. 2. Francis GS, Siegel RM, Goldsmith SR, Olivari MT, Levine TB, Cohn JN. Acute vasoconstrictor response to intravenous furosemide in patients with chronic congestive heart failure: Activation of the neurohumoral axis. Ann Intern Med 1985; 103: 1–6.

3. 3. Kinugawa K, Sato N, Inomata T. Effects of tolvaptan on volume overload in patients with heart failure. Int Heart J 2018; 59: 1368–1377.

4. 4. Imamura T, Kinugawa K. Update of acute and long-term tolvaptan therapy. J Cardiol 2019; 73: 102–107.

5. 5. Imamura T, Kinugawa K, Fujino T, Inaba T, Maki H, Hatano M, et al. Increased urine aquaporin-2 relative to plasma arginine vasopressin is a novel marker of response to tolvaptan in patients with decompensated heart failure. Circ J 2014; 78: 2240–2249.

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Kidney-tonifying blood-activating decoction delays ventricular remodeling in rats with chronic heart failure by regulating gut microbiota and metabolites and p38 mitogen-activated protein kinase/p65 nuclear factor kappa-B/aquaporin-4 signaling pathway;Journal of Ethnopharmacology;2024-08

2. Impact of tolvaptan add-on treatment on patients with heart failure requiring long-term congestion management: A retrospective cohort study using a medical claim database in Japan;Journal of Cardiology;2022-12

3. Early initiation of tolvaptan is associated with early discharge in patients with heart failure regardless of age;BMC Cardiovascular Disorders;2022-04-29

4. Cost-Effectiveness of long-term tolvaptan administration for chronic heart failure treatment in Japan;Journal of Cardiology;2022-03

5. Temporal Change in Renoprotective Effect of Tolvaptan on Patients with Heart Failure: AURORA Study;Journal of Clinical Medicine;2022-02-13